326 related articles for article (PubMed ID: 38533510)
21. Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer.
Martinis E; Ricci C; Trevisan C; Tomadini G; Tonon S
Pharmaceutics; 2023 Jul; 15(7):. PubMed ID: 37514155
[TBL] [Abstract][Full Text] [Related]
22. From bench to bedside: the history and progress of CAR T cell therapy.
Mitra A; Barua A; Huang L; Ganguly S; Feng Q; He B
Front Immunol; 2023; 14():1188049. PubMed ID: 37256141
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial.
Gögenur M; Balsevicius L; Bulut M; Colak N; Justesen TF; Fiehn AK; Jensen MB; Høst-Rasmussen K; Cappelen B; Gaggar S; Tajik A; Zahid JA; Bennedsen ALB; D'Ondes TDB; Raskov H; Sækmose SG; Hansen LB; Salanti A; Brix S; Gögenur I
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37172969
[TBL] [Abstract][Full Text] [Related]
24. Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer.
Aldilaijan AF; Kim YI; Kim CW; Yoon YS; Park IJ; Lim SB; Kim J; Ro JS; Kim JC
Sci Rep; 2023 May; 13(1):7616. PubMed ID: 37165043
[TBL] [Abstract][Full Text] [Related]
25. Progress in the clinical application of immune checkpoint inhibitors in small cell lung cancer.
He J; Hu Q
Front Immunol; 2023; 14():1126582. PubMed ID: 37063927
[TBL] [Abstract][Full Text] [Related]
26. Promise of dostarlimab in cancer therapy: Advancements and cross-talk considerations.
Babar Q; Saeed A; Murugappan S; Dhumal D; Tabish T; Thorat ND
Drug Discov Today; 2023 Jun; 28(6):103577. PubMed ID: 37004983
[TBL] [Abstract][Full Text] [Related]
27. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
[TBL] [Abstract][Full Text] [Related]
28. CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.
Maher J; Davies DM
Biology (Basel); 2023 Feb; 12(2):. PubMed ID: 36829563
[TBL] [Abstract][Full Text] [Related]
29. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
Monge C; Xie C; Myojin Y; Coffman K; Hrones DM; Wang S; Hernandez JM; Wood BJ; Levy EB; Juburi I; Hewitt SM; Kleiner DE; Steinberg SM; Figg WD; Redd B; Homan P; Cam M; Ruf B; Duffy AG; Greten TF
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754451
[TBL] [Abstract][Full Text] [Related]
30. Exosomes as smart drug delivery vehicles for cancer immunotherapy.
Zhang H; Wang S; Sun M; Cui Y; Xing J; Teng L; Xi Z; Yang Z
Front Immunol; 2022; 13():1093607. PubMed ID: 36733388
[TBL] [Abstract][Full Text] [Related]
31. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
Garralda E; Sukari A; Lakhani NJ; Patnaik A; Lou Y; Im SA; Golan T; Geva R; Wermke M; de Miguel M; Palcza J; Jha S; Chaney M; Abraham AK; Healy J; Falchook GS
ESMO Open; 2022 Dec; 7(6):100639. PubMed ID: 36493599
[TBL] [Abstract][Full Text] [Related]
32. Model-based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors.
Budha N; Wu CY; Tang Z; Yu T; Liu L; Xu F; Gao Y; Li R; Zhang Q; Wan Y; Sahasranaman S
CPT Pharmacometrics Syst Pharmacol; 2023 Jan; 12(1):95-109. PubMed ID: 36330700
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
Tan TJ; Ang WXG; Wang WW; Chong HS; Tan SH; Cheong R; Chia JW; Syn NL; Shuen WH; Ba R; Kaliaperumal N; Au B; Hopkins R; Li X; Tan AC; Seet AOL; Connolly JE; Arkachaisri T; Chew V; Lajam ABM; Guo D; Chew MZW; Wasser M; Kumar P; Albani S; Toh HC
Nat Commun; 2022 Oct; 13(1):6453. PubMed ID: 36307410
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in CAR-T cells therapy for colorectal cancer.
Qin X; Wu F; Chen C; Li Q
Front Immunol; 2022; 13():904137. PubMed ID: 36238297
[TBL] [Abstract][Full Text] [Related]
35. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers.
Tang Q; Chen Y; Li X; Long S; Shi Y; Yu Y; Wu W; Han L; Wang S
Front Immunol; 2022; 13():964442. PubMed ID: 36177034
[TBL] [Abstract][Full Text] [Related]
36. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
Español-Rego M; Fernández-Martos C; Elez E; Foguet C; Pedrosa L; Rodríguez N; Ruiz-Casado A; Pineda E; Cid J; Cabezón R; Oliveres H; Lozano M; Ginés A; García-Criado A; Ayuso JR; Pagés M; Cuatrecasas M; Torres F; Thomson T; Cascante M; Benítez-Ribas D; Maurel J
Cancer Immunol Immunother; 2023 Apr; 72(4):827-840. PubMed ID: 36083313
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
Johnson B; Haymaker CL; Parra ER; Soto LMS; Wang X; Thomas JV; Dasari A; Morris VK; Raghav K; Vilar E; Kee BK; Eng C; Parseghian CM; Wolff RA; Lee Y; Lorenzini D; Laberiano-Fernandez C; Verma A; Lang W; Wistuba II; Futreal A; Kopetz S; Overman MJ
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36007963
[TBL] [Abstract][Full Text] [Related]
38. Colorectal cancer vaccines: The current scenario and future prospects.
Jia W; Zhang T; Huang H; Feng H; Wang S; Guo Z; Luo Z; Ji X; Cheng X; Zhao R
Front Immunol; 2022; 13():942235. PubMed ID: 35990683
[TBL] [Abstract][Full Text] [Related]
39. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application.
Huo JL; Wang YT; Fu WJ; Lu N; Liu ZS
Front Immunol; 2022; 13():956090. PubMed ID: 35958563
[TBL] [Abstract][Full Text] [Related]
40. Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody.
Zhang L; Geng Z; Hao B; Geng Q
Cancer Control; 2022; 29():10732748221111296. PubMed ID: 35926155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]